Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases

Human Gene Therapy Methods

Volumn 23, Issue 6, 2012, Pages 357-365

  Gesheva, Vera ^a   Szekeres, Zsuzsanna ^b   Mihaylova, Nikolina ^a   Dimitrova, Iliyana ^a   Nikolova, Maria ^c   Erdei, Anna ^b,d   Prechl, Jozsef ^b   Tchorbanov, Andrey ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b MTA ELTE Immunology Research Group Eötvös University   (Hungary)

^c NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; DNA ANTIBODY; DNA LIKE PEPTIDE 2.4G2 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; DNA LIKE PEPTIDE 7G6 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; DNA VACCINE; DOUBLE STRANDED DNA; FC RECEPTOR IIB; GAMMA INTERFERON; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; NAKED DNA; PLASMID DNA; UNCLASSIFIED DRUG;

ALLERGIC GLOMERULONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA CROSS LINKING; EUKARYOTIC CELL; FEMALE; GENE EXPRESSION; GENE INSERTION; GENE VECTOR; GENETIC ENGINEERING; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MONONUCLEAR CELL; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTINUCLEAR; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENETIC ENGINEERING; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; PEPTIDES; PLASMIDS; SINGLE-CHAIN ANTIBODIES;

EID: 84878746343     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.051     Document Type: Article

References (54)

1. Ahuja, A., Shupe, J., Dunn, R., et al. (2007). Depletion of B cells in murine lupus: Efficacy and resistance. J. Immunol. 179, 3351-3361.
2. Anolik, J.H., Barmard, J., Cappione, A., et al. (2004). Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580-3590. (Pubitemid 39488683)
3. Anolik, J.H., Barnard, J., Owen, T., et al. (2007). Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044-3056. (Pubitemid 47502752)
4. Auyeung-Kim, D.J., Devalaraja, M.N., Migone, T.S., et al. (2009). Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod. Toxicol. 28, 443-455.
5. Baker, K.P., Edwards, B.M., Main, S.H., et al. (2003). Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253-3265. (Pubitemid 37409340)
6. Bauminger, S., and Wilchek, M. (1980). The use of carbodiimides in the preparation of immunizing conjugates. Methods Enzymol. 70, 151-159.
7. Bobe, P., Bonardelle, D., Benihoud, K., et al. (2006). Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 108, 3967-3975. (Pubitemid 44913262)
8. Brown, K., Blair, D., Reid, S., et al. (2004). FccRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPkinase-phosphatase, Pac-1, and the 3¢-inositol phosphatase, PTEN. Cell. Signal. 16, 71-80. (Pubitemid 37357193)
9. Carter, N., and Harnett, M. (2004). Dissection of the signalling mechanisms underlying Fcc RIIB-mediated apoptosis of mature B-cells. Biochem. Soc. Trans. 32, 973-975. (Pubitemid 39655519)
10. Chan, O., and Shlomchik, M. (1998). A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160, 51-59. (Pubitemid 28116714)
11. Chan, O., Hannum, L.G., Haberman, A.M., et al. (1999). A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189, 1639-1648.
12. Chang, Y., Yap, S., Ge, X., et al. (2005). DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Gene Ther. 12, 1679-1685. (Pubitemid 41679171)
13. Dong, J., Wang, Q.-X., Zhou, C.-Y., et al. (2007). Activation of the STAT1 signaling pathway in lupus nephritis in MRL/lpr mice. Lupus 6, 101-109. (Pubitemid 46347932)
14. Dooley, M.A., Cosio, F.G., Nachman, P.H., et al. (1999). Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J. Am. Soc. Nephrol. 10, 833-839. (Pubitemid 29149534)
15. Dorner, T. (2010). Therapy: Hydroxychloroquine in SLE: Old drug, new perspectives. Nat. Rev. Rheumatol. 6, 10-11.
16. Dorner, T., Kaufmannn, J., Wegener, W., et al. (2006). Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74.
17. Edwards, J.C., Szczepanski, L., Szechinski, J., et al. (2004). Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581. (Pubitemid 38758544)
18. Ehrenstein, M., Katz, D., Griffiths, M., et al. (1995). Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 48, 705-711.
19. Eisenberg, R., and Looney, R.J. (2005). The therapeutic potential of anti-CD20: "What do B-cells do?" Clin. Immunol. 117, 207-213. (Pubitemid 43005207)
20. Ferrera, F., Hahn, B., Rizzi, M., et al. (2007). Protection against renal disease in (NZB ·NZW)F1 lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum. 56, 1945-1953. (Pubitemid 47110393)
21. Gaynor, B., Putterman, C., Valadon, P., et al. (1997). Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc. Natl. Acad. Sci. U.S.A. 94, 1955-1960. (Pubitemid 27113943)
22. Haas, C., Ryffel, B., and Le, H.M. (1997). IFN-c is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158, 5484-5491. (Pubitemid 127681257)
23. Horton, H., Chu, S., Ortiz, E., et al. (2011). Antibody-mediated coengagement of FccRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol. 186, 4223-4233.
24. Hwang, W.Y., and Foote, J. (2005). Immunogenicity of engineered antibodies. Methods 36, 3-10. (Pubitemid 40558811)
25. Kaliyaperumal, A., Michaels, M.A., and Datta, S.K. (1999). Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol. 162, 5775-5783. (Pubitemid 29314928)
26. Kalsi, J.K., Martin, A.C., Hirabayashi, Y., et al. (1996). Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol. Immunol. 33, 471-483.
27. Kang, I., and Park, S.H. (2003). Infectious complications in SLE after immunosuppressive therapies. Curr. Opin. Rheumatol. 15, 528-534. (Pubitemid 37041388)
28. Marino, M., Ruvo, M., De Falco, S., and Fassina, G. (2000). Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol. 18, 735-739. (Pubitemid 30460688)
29. Martinez, N.R., Augstein, P., Moustakas, A.K., et al. (2003). Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J. Clin. Invest. 111, 1365-1371. (Pubitemid 36554707)
30. Mihaylova, N., Voynova, E., Tchorbanov, A., et al. (2008). Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their FccIIb receptor. Int. Immunol. 20, 165-175. (Pubitemid 351234383)
31. Mihaylova, N., Voynova, E., Tchorbanov, A., et al. (2009). Simultaneous engagement of FccIIb and CD22 inhibitory receptors suppresses the activity of targeted autoreactive B cells. Mol. Immun. 47, 123-130.
32. Miller, S.D., Turley, D.M., and Podojil, J.R. (2007). Antigenspecific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. 7, 665-677. (Pubitemid 47327394)
33. Monneaux, F., and Muller, S. (2009). Molecular therapies for systemic lupus erythematosus: Clinical trials and future prospects. Arthritis Res. Ther. 11, 234.
34. Nepom, G.T. (2002). Therapy of autoimmune diseases: Clinical trials and new biologics. Curr. Opin. Immunol. 14, 812-815. (Pubitemid 35292431)
35. Nikolova, K., Tchorbanov, A., Djoumerska-Alexieva, I., et al. (2009). Intravenous immunoglobulin up-regulates the expression of the inhibitory FccIIB receptor on B cells. Immunol. Cell Biol. 87, 529-533.
36. O'Shea, J., Ma, A., and Lipski, P. (2001). Cytokines and autoimmunity. Nat. Rev. 2, 37-45. (Pubitemid 37328774)
37. Peng, S., Moslehi, J., and Craft, J. (1997). Roles of interferon-c and interleukin-4 in murine lupus. J. Clin. Invest. 8, 1936-1946. (Pubitemid 27175941)
38. Prechl, J., Tchorbanov, A., Horvath, A., et al. (1999). Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacology 42, 159-165. (Pubitemid 29322298)
39. Presta, L.G. (2006). Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58, 640-656. (Pubitemid 44262411)
40. Pugliese, A. (2003). Peptide-based treatment for autoimmune diseases: Learning how to handle a double-edged sword. J. Clin. Invest. 111, 1280-1282. (Pubitemid 36554697)
41. Putterman, C. (2004). New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun. Rev. 3, 7-11. (Pubitemid 38293360)
42. Putterman, C., and Diamond, B. (1998). Immunization with a peptide surrogate for dsDNA induces autoantibody production and renal immunoglobulin deposition. J. Exp. Med. 188, 29-38. (Pubitemid 28328603)
43. Putterman, C., Deocharan, B., and Diamond, B. (2000). Molecular analysis of the autoantibody response in peptideinduced autoimmunity. J. Immunol. 164, 2542-2549. (Pubitemid 30115484)
44. Ravetch, J.V., and Lanier, L.L. (2000). Immune inhibitory receptors. Science 290, 84-89.
45. Schwarting, A., Wada, T., Kinoshita, K., et al. (1998). IFN-c receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Faslpr mice. J. Immunol. 161, 494-503. (Pubitemid 28285560)
46. Shlomchik, M.J., Madaio, M.P., Ni, D., et al. (1994). The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180, 1295-1306. (Pubitemid 24289603)
47. Stoll, M.L., Price, K.D., Silvin, C.J., et al. (2007). Immunization with peptides derived from the idiotypic region of lupusassociated autoantibodies delays the development of lupus nephritis in the (SWR · NZB)F1 murine model. J. Autoimmun. 29, 30-37. (Pubitemid 47016911)
48. Szekeres, Z., Herbath, M., Angyal, A., et al. (2010). Modulation of immune response by combined targeting of complement receptors and low-affinity Fcc receptors. Immunol. Lett. 130, 66-73.
49. Takeuchi, K., Inada, M., Miyashima, S., et al. (1998). A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 12, 4616-4623. (Pubitemid 28270310)
50. Tarasenko, T., Dean, J.A., and Boland, S. (2007). FccRIIb as a modulator of autoimmune disease susceptibility. Autoimmunity 40, 409-417. (Pubitemid 47343352)
51. Tchorbanov, A., Voynova, E., Mihaylova, N., et al. (2007). Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 37, 3587-3596.
52. Toubi, E., Rosner, I., Rozenbaum, M., et al. (2000). The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9, 92-95. (Pubitemid 30171104)
53. Venkatesh, J., Kawabata, D., Kim, S., et al. (2009). Selective regulation of autoreactive B cells by FccRIIb. J. Autoimmun. 32, 149-157.
54. Xiang, Z., Cutler, A., Brownlie, R., et al. (2007). FccRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8, 419-429. (Pubitemid 46745417)